Single agent chemotherapy of advanced lung cancer is still unsatisfactory. The most encouraging results have been obtained with high dose intermittent treatment with cyclophosphamide, methotrexate or adriamycin. Combination chemotherapy is probably more efficacious than single agent chemotherapy, especially in oat cell carcinoma. The best treatment schedules give a response rate of approximately 80%. The value of adjuvant chemotherapy is not yet established, but new controlled clinical trials are indicated considering the poor results achieved by surgery and radiotherapy.SCOPUS: NotDefined.jinfo:eu-repo/semantics/publishe
MODEST RESULTS TILL NOW: Despite progress in the treatment of bronchial cancer (BC) over the last 20...
Following three courses of induction chemotherapy, 23 patients with small cell carcinoma of the lung...
The clinical experience with chemotherapy in mycosis fungoides is practically limited to the action ...
Multiple-drug chemotherapy has markedly improved the survival of patients with non oat-cell bronchia...
In approximately 80% of the patients with limited disease, the administration of treatment, either c...
The administration of multiple cytostatic drugs on a weekly basis has been proposed as a new intensi...
Chemotherapy in non-small cell bronchial carcinoma Each year about 40 000 people in the United King-...
The multidisciplinary management of lung cancer has been universally accepted. In France, the multid...
Le cancer du poumon représente la première cause de mortalité par cancer en France ainsi qu'au nivea...
A review of the published clinical trials of surgical adjuvant chemotherapy in lung cancer indicated...
Chemotherapy has been playing a major role in the treatment of various cancers especially in advance...
Chemotherapy in the status of treating advanced Non-Small Cell Lung Cancer (NSCLC) was established i...
Radiation therapy has been for years the treatment of choice of locally advanced non small cell lung...
Over 85 % of patients with non small cell lung carcinoma (NSCLC) have no EGFR activating mutation, t...
Non-small cell lung cancer (NSCLC) accounts for more than 80 % of diagnosed lung cancer cases and is...
MODEST RESULTS TILL NOW: Despite progress in the treatment of bronchial cancer (BC) over the last 20...
Following three courses of induction chemotherapy, 23 patients with small cell carcinoma of the lung...
The clinical experience with chemotherapy in mycosis fungoides is practically limited to the action ...
Multiple-drug chemotherapy has markedly improved the survival of patients with non oat-cell bronchia...
In approximately 80% of the patients with limited disease, the administration of treatment, either c...
The administration of multiple cytostatic drugs on a weekly basis has been proposed as a new intensi...
Chemotherapy in non-small cell bronchial carcinoma Each year about 40 000 people in the United King-...
The multidisciplinary management of lung cancer has been universally accepted. In France, the multid...
Le cancer du poumon représente la première cause de mortalité par cancer en France ainsi qu'au nivea...
A review of the published clinical trials of surgical adjuvant chemotherapy in lung cancer indicated...
Chemotherapy has been playing a major role in the treatment of various cancers especially in advance...
Chemotherapy in the status of treating advanced Non-Small Cell Lung Cancer (NSCLC) was established i...
Radiation therapy has been for years the treatment of choice of locally advanced non small cell lung...
Over 85 % of patients with non small cell lung carcinoma (NSCLC) have no EGFR activating mutation, t...
Non-small cell lung cancer (NSCLC) accounts for more than 80 % of diagnosed lung cancer cases and is...
MODEST RESULTS TILL NOW: Despite progress in the treatment of bronchial cancer (BC) over the last 20...
Following three courses of induction chemotherapy, 23 patients with small cell carcinoma of the lung...
The clinical experience with chemotherapy in mycosis fungoides is practically limited to the action ...